Cytek Biosciences Inc (CTKB)

$5.3

-0.14

(-2.57%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $5.27
    $5.48
    $5.30
    downward going graph

    0.66%

    Downside

    Day's Volatility :3.92%

    Upside

    3.28%

    downward going graph
  • $3.80
    $9.87
    $5.30
    downward going graph

    28.3%

    Downside

    52 Weeks Volatility :61.5%

    Upside

    46.3%

    downward going graph

Returns

PeriodCytek Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-11.67%
5.1%
0.0%
6 Months
-25.93%
4.9%
0.0%
1 Year
-22.85%
16.6%
0.0%
3 Years
-77.88%
13.2%
-22.3%

Highlights

Market Capitalization
697.0M
Book Value
$2.96
Earnings Per Share (EPS)
-0.14
Wall Street Target Price
8.7
Profit Margin
-8.88%
Operating Margin TTM
-18.29%
Return On Assets TTM
-3.01%
Return On Equity TTM
-4.32%
Revenue TTM
197.7M
Revenue Per Share TTM
1.49
Quarterly Revenue Growth YOY
-6.2%
Gross Profit TTM
101.0M
EBITDA
-17.4M
Diluted Eps TTM
-0.14
Quarterly Earnings Growth YOY
0.66
EPS Estimate Current Year
-0.08
EPS Estimate Next Year
0.04
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
-0.01

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Cytek Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 64.15%

Current $5.30
Target $8.70

Company Financials

FY19Y/Y Change
Revenue
57.9M
-
Net Income
-16.8M
-
Net Profit Margin
-29.07%
-
FY20Y/Y Change
Revenue
92.8M
↑ 60.39%
Net Income
19.4M
↓ 215.36%
Net Profit Margin
20.91%
↑ 49.98%
FY21Y/Y Change
Revenue
128.0M
↑ 37.82%
Net Income
4.4M
↓ 77.24%
Net Profit Margin
3.45%
↓ 17.46%
FY22Y/Y Change
Revenue
164.0M
↑ 28.2%
Net Income
2.6M
↓ 41.68%
Net Profit Margin
1.57%
↓ 1.88%
FY23Y/Y Change
Revenue
193.0M
↑ 17.67%
Net Income
-12.1M
↓ 571.58%
Net Profit Margin
-6.29%
↓ 7.86%
Q1 FY23Q/Q Change
Revenue
37.1M
↓ 23.27%
Net Income
-6.8M
↓ 292.89%
Net Profit Margin
-18.35%
↓ 25.65%
Q2 FY23Q/Q Change
Revenue
49.7M
↑ 33.99%
Net Income
-4.4M
↓ 35.54%
Net Profit Margin
-8.83%
↑ 9.52%
Q3 FY23Q/Q Change
Revenue
48.0M
↓ 3.41%
Net Income
-6.5M
↑ 47.13%
Net Profit Margin
-13.45%
↓ 4.62%
Q4 FY23Q/Q Change
Revenue
58.2M
↑ 21.32%
Net Income
5.5M
↓ 185.24%
Net Profit Margin
9.45%
↑ 22.9%
Q1 FY24Q/Q Change
Revenue
44.9M
↓ 22.96%
Net Income
-6.2M
↓ 212.1%
Net Profit Margin
-13.75%
↓ 23.2%
Q2 FY24Q/Q Change
Revenue
46.6M
↑ 3.92%
Net Income
-10.4M
↑ 69.14%
Net Profit Margin
-22.38%
↓ 8.63%
FY19Y/Y Change
Total Assets
70.4M
-
Total Liabilities
112.1M
-
FY20Y/Y Change
Total Assets
220.0M
↑ 212.64%
Total Liabilities
236.0M
↑ 110.6%
FY21Y/Y Change
Total Assets
463.7M
↑ 110.79%
Total Liabilities
56.9M
↓ 75.89%
FY22Y/Y Change
Total Assets
519.5M
↑ 12.03%
Total Liabilities
93.9M
↑ 65.08%
FY23Y/Y Change
Total Assets
497.7M
↓ 4.2%
Total Liabilities
104.6M
↑ 11.36%
Q1 FY23Q/Q Change
Total Assets
524.6M
↑ 0.98%
Total Liabilities
101.1M
↑ 7.65%
Q2 FY23Q/Q Change
Total Assets
525.1M
↑ 0.09%
Total Liabilities
100.9M
↓ 0.24%
Q3 FY23Q/Q Change
Total Assets
519.4M
↓ 1.07%
Total Liabilities
103.9M
↑ 3.0%
Q4 FY23Q/Q Change
Total Assets
497.7M
↓ 4.19%
Total Liabilities
104.6M
↑ 0.67%
Q1 FY24Q/Q Change
Total Assets
492.1M
↓ 1.13%
Total Liabilities
99.5M
↓ 4.93%
Q2 FY24Q/Q Change
Total Assets
483.7M
↓ 1.7%
Total Liabilities
94.6M
↓ 4.88%
FY19Y/Y Change
Operating Cash Flow
-13.7M
-
Investing Cash Flow
-973.0K
-
Financing Cash Flow
93.0K
-
FY20Y/Y Change
Operating Cash Flow
15.2M
↓ 210.25%
Investing Cash Flow
-1.5M
↑ 58.99%
Financing Cash Flow
122.6M
↑ 131735.48%
FY21Y/Y Change
Operating Cash Flow
4.6M
↓ 69.45%
Investing Cash Flow
-21.0M
↑ 1257.01%
Financing Cash Flow
213.6M
↑ 74.18%
FY22Y/Y Change
Operating Cash Flow
-12.2M
↓ 364.17%
Investing Cash Flow
-55.9M
↑ 166.32%
Financing Cash Flow
5.5M
↓ 97.42%
Q1 FY23Q/Q Change
Operating Cash Flow
2.9M
↓ 53.85%
Investing Cash Flow
-168.9M
↑ 230.71%
Financing Cash Flow
203.0K
↓ 94.73%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.9M
↓ 199.72%
Investing Cash Flow
2.8M
↓ 101.65%
Financing Cash Flow
216.0K
↑ 6.4%

Technicals Summary

Sell

Neutral

Buy

Cytek Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cytek Biosciences Inc
Cytek Biosciences Inc
4.13%
-25.93%
-22.85%
-77.88%
-71.75%
Stryker Corporation
Stryker Corporation
12.3%
0.36%
24.19%
28.8%
65.26%
Boston Scientific Corp.
Boston Scientific Corp.
10.6%
20.32%
51.42%
80.93%
95.5%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
9.4%
-28.78%
-12.2%
-45.23%
-7.73%
Abbott Laboratories
Abbott Laboratories
3.57%
-5.84%
13.1%
-11.32%
35.19%
Medtronic Plc
Medtronic Plc
10.85%
5.57%
12.46%
-33.2%
-16.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cytek Biosciences Inc
Cytek Biosciences Inc
351.5
NA
NA
-0.08
-0.04
-0.03
NA
2.96
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cytek Biosciences Inc
Cytek Biosciences Inc
Buy
$697.0M
-71.75%
351.5
-8.88%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
65.26%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
95.5%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-7.73%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
35.19%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.71%
30.16
12.06%

Insights on Cytek Biosciences Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 44.86M → 46.61M (in $), with an average increase of 3.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 5.50M → -10.43M (in $), with an average decrease of 140.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 74.3%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 158.8%

Institutional Holdings

  • BlackRock Inc

    12.98%

  • Vanguard Group Inc

    8.93%

  • Brown Capital Management, LLC

    8.66%

  • Hillhouse Capital Advisors, Ltd.

    5.06%

  • State Street Corporation

    3.13%

  • New York State Common Retirement Fund

    2.24%

Company Information

Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches.

Organization
Cytek Biosciences Inc
Employees
645
CEO
Dr. Wenbin Jiang Ph.D.
Industry
Healthcare

Discover More

FAQs